10 completed, 1 terminated, 1 unknown. 9 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 7, Terminated 1, Unknown 1 |
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 1 | Completed 1 |
Follow UNION therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS) Orismilast modified release tablets, Placebo - Atopic Dermatitis, Skin Diseases | Phase 2 | Completed | UNION therapeutics | 235 | 2022-07-11 | 2025-03-07 |
| Study to Assess the Efficacy and Safety of Orismilast in Psoriasis Orismilast modified release tablets, Placebo - Psoriasis, Skin Diseases | Phase 2 | Completed | UNION therapeutics | 202 | 2021-12-30 | 2024-04-16 |
| Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa Orismilast - Hidradenitis Suppurativa | Phase 2 | Unknown | Gregor Jemec | 24 | 2021-10-01 | 2021-09-28 |
| Safety and Efficacy of Intranasal Administration of Niclosamide (UNI91103) in Adults With Asymptomatic or Mild COVID-19 Niclosamide, Placebo - Covid19 | Phase 2 | Terminated | UNION therapeutics | 4 | 2021-09-03 | 2022-02-21 |
| PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V Niclosamide, Placebo, Ciclesonide - Covid19 | Phase 2 / Phase 3 | Completed | Cambridge University Hospitals NHS Foundation Trust | 2240 | 2021-02-19 | 2025-06-20 |
| Safety of Ascending Doses of Niclosamide (UNI911 INHALATION) in Healthy Volunteers UNI911 inhalation 1% and intranasal spray 1%, Placebo - Covid19 | Phase 1 | Completed | UNION therapeutics | 64 | 2020-06-29 | 2021-08-26 |
| Study to Evaluate Safety & Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults With Mild to Moderate AD ATx201, ATx201 OINTMENT vehicle - Atopic Dermatitis | Phase 2 | Completed | UNION therapeutics | 220 | 2019-10-22 | 2021-04-29 |
| Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo ATx201, ATx201 GEL Vehicle - Impetigo | Phase 2 | Completed | UNION therapeutics | 210 | 2018-02-23 | 2018-07-31 |
| Sensitization Study of ATx201 in Healthy Volunteers ATx201, ATx201 Placebo Gel - Sensitivity, Contact | Phase 1 | Completed | UNION therapeutics | 240 | 2018-01-08 | 2018-05-07 |
| A Study to Evaluate the Irritation Potential of ATx201 in Healthy Volunteers ATx201 Gel 2%, ATx201 Gel 4%, Positive Control - Irritation Potential of Topic Agent | Phase 1 | Completed | UNION therapeutics | 36 | 2017-10-04 | 2019-01-16 |
| A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis ATx201 2% Cream, ATx201 Cream Vehicle - Atopic Dermatitis | Phase 2 | Completed | UNION therapeutics | 31 | 2017-09-25 | 2018-03-20 |
| Evaluation of ATx201 as a Topical Antibiotic Agent ATx201 dermal formulations 2% - Infection, Bacterial | Phase 1 / Phase 2 | Completed | UNION therapeutics | 73 | 2016-12-01 | 2018-03-20 |
COVID-19 (3) · Dermatitis, Atopic (3) · Skin Diseases (2) · Bacterial Infections (1) · Dermatitis, Contact (1) · Glomerulonephritis (1) · Hidradenitis Suppurativa (1) · Impetigo (1) · Lupus Erythematosus, Systemic (1) · Neoplasms (1) · Psoriasis (1) · Vasculitis (1)
Niclosamide (2) · ciclesonide (1) · sotrovimab (1)
United States (4) · Germany (3) · Poland (3) · Denmark (2) · United Kingdom (2) · Austria (1) · Bulgaria (1) · Canada (1) · Hungary (1) · South Africa (1)
Philippe Prokocimer, MD (3) · Gregor Jemec, Professor (1) · Jesper Sonne, MD, DMSci (1) · Markus Zeitlinger, MD (1) · P. A. MD (1) · P. A., MD (1) · Peter Heymer, MD (1) · Philippe Andres, Dr. (1) · Philippe Prokocimer (1) · Rona Smith, Dr (1)